Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Sustainability

Hovione is committed to doing its part for a better world.

Page
Read more

Epidel™

Epidel™ is an innovative technology with the ability to deliver sustained-release pharmaceuticals via surface erosion resulting in the ability to precisely tune pharmacokinetics to meet the target indication needs.

Page
Read more

GMP Certificates

GMP Certificates

Page
Read more